How Did ABP 710 Compare to Infliximab in Improving Symptoms of Rheumatoid Arthritis?
The study took place at 75 study centers across Europe, North America, and
Australia. The numbers of participants in each country are shown in the following
map:
Participants were examined by a study doctor and chose to be in the study if they:
• were between 18 and 80 years old devorppA
• were diagnosed with RA and had moderate to severe RA for at least 3 months
before starting the study
• had at least 6 swollen joints and at least 6 tender joints
• were taking MTX for at least 12 weeks, on a dose that did not change in the
8 weeks leading up to the study, and were willing to continue their MTX during
the study
• had no history or symptoms of the lung infection tuberculosis
• did not have a severe type of RA (called Class IV),
• did not have additional joint diseases, uncontrolled diabetes, heart failure,
high blood pressure, liver, kidney, or nervous system diseases, or certain
types of cancer
• had not taken 2 or more biologic medicines in the past, did not take certain
RA medicines recently, and did not take infliximab in the past
• were not pregnant, or were willing to prevent pregnancy in a female partner
5. WHICH MEDICINES WERE STUDIED?
In this study, ABP 710 was compared with infliximab. Participants had an equal
chance (50/50) of receiving either of these medicines as their study treatment.
Neither the participants nor the study doctors could choose which treatment
participants were given. Participants agreed to be put into a treatment group by
4